THE MODERN BIOHEALTH, WITH PERSPECTIVE.
Clinician-led care in Florida

PEPTIDE ATLAS / ENERGY & LONGEVITY / ELAMIPRETIDE

EvidenceAccelerated approval; confirmation pending
The existing guide’s evidence label applies only to the specific context discussed. Read the sources and limitations; this is not medical approval.
RegulatoryFDA-approved
Approval belongs to an exact product, formulation and indication. It does not establish availability here or approval of all uses.
Corrections & editorial standards

Elamipretide

Editorial visualization for energy & longevity peptide research
THE SIGNAL MAP · ENERGY & LONGEVITY
ALSO KNOWN ASForzinity · SS-31

The first FDA-approved Barth syndrome therapy; approval does not establish general mitochondrial enhancement.

01CATEGORYEnergy & longevity
02REGULATORY STATUSFDA-approved
03COMMON ROUTESubcutaneous injection
04REVIEW STANDARDProduct, indication and evidence

HOW TO USE THIS PAGE

Read the profile in the order that protects the decision.

  1. 01
    Verify what it is

    Confirm the exact molecule, route, regulatory lane and actual human evidence.

  2. 02
    Read the evidence limits

    Unsupported claims, contraindications and uncertainty come before any protocol.

  3. 03
    Build the monitoring plan

    Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.

RESEARCH PASSPORT

The five facts to know first.

HUMAN EVIDENCEAccelerated approval; confirmation pending

Evidence strength for the context described on this page.

REGULATORY LANEFDA-approved

Status is product-, formulation- and indication-specific.

CLINICAL CONTEXTIndividual evaluation required

Public education does not establish a personal treatment plan.

SOURCE PACK3 direct source links

Plus 0 research searches. A search link is not a cited study or proof of a claim.

TESTED ATHLETESVerify the exact ingredient.

Peptide hormones, growth factors and related substances may be prohibited.

Check Global DRO ↗
Know the review boundary.

Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.

How we describe evidence →

OVERVIEW

What Elamipretide is.

A mitochondria-targeting tetrapeptide that binds cardiolipin. In 2025 the FDA granted accelerated approval for a narrow rare-disease indication based on an intermediate muscle-strength endpoint.

HOW IT IS THOUGHT TO WORK

Targets the inner mitochondrial membrane and cardiolipin with the goal of stabilizing membrane function in Barth syndrome.

REGULATORY SOURCE CHECK · November 8, 2026

Forzinity received accelerated FDA approval to improve muscle strength in patients with Barth syndrome who weigh at least 30 kg. Approval rests on an intermediate endpoint; a confirmatory trial must establish patient benefit. This does not establish general energy or longevity benefits.

Read the FDA approval and evidence requirements ↗

This checks the stated regulatory point only, not every clinical claim in the profile.

EFFECTS & EVIDENCE

What the evidence supports—and what it does not.

SUPPORTED IN CONTEXT
  • Improved knee-extensor muscle strength in the labeled Barth syndrome population weighing at least 30 kg
  • Continued approval depends on confirmatory evidence
NOT ESTABLISHED
  • General energy enhancement
  • Healthy longevity
  • Athletic mitochondrial optimization
  • Benefit in people without Barth syndrome

Evidence grade: Accelerated approval; confirmation pending. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.

CLINICAL CONTEXT

The decision is individual.

Approval applies to a specific product and indication. A licensed clinician must evaluate whether the exact treatment fits your history, current medications and goals.

What is the exact claim?

Identify the outcome, formulation and population actually studied.

What would change the decision?

Review benefits, uncertainty, contraindications and better-studied alternatives.

Who owns follow-up?

A treatment decision needs a responsible clinician, monitoring and a review date.

This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.

MONITORING

What should be tracked.

  • Muscle strength and functional outcomes
  • Injection-site reactions
  • Hypersensitivity
  • Disease-specific cardiology and metabolic care

SAFETY

Risks, red flags and reasons to avoid it.

KNOWN OR PLAUSIBLE RISKS
  • Injection-site reactions
  • Hypersensitivity
  • Limited approval population and evidence base
  • Unknown benefit-risk for wellness use
AVOID / ESCALATE
  • Off-label wellness sourcing
  • Products not supplied through the approved prescription chain
  • Assuming mitochondrial targeting equals anti-aging
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.

CLINICIAN VISIT CHECKLIST

Six questions worth bringing with you.

01What exact product is this?

Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.

02What outcome are we treating?

Name the diagnosis or target, how it will be measured and the realistic time to reassess.

03Why this option?

Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.

04Where did the dose come from?

Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.

05What is the monitoring plan?

Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.

06How is quality verified?

Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.

Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.

SOURCES & RESEARCH LINKS

Read the record yourself.

We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.

PRODUCTS & TREATMENT ACCESS

Use a verified prescription pathway.

AVAILABILITY

Specialty prescription product for eligible Barth syndrome patients.

MARKET REALITY

This 2025 approval changed elamipretide's status, but only for a rare disease. It did not validate the broader longevity market built around SS-31.

MODERN BIO AVAILABILITY

Learn now. Verify care separately.

This guide is not a booking or prescribing service. Clinical appointments and prescription decisions are handled separately from this educational Atlas.

Review care readiness and standards →

NEXT STEP

Return to energy & longevity peptides.

Explore the category →

YOUR NEXT STEP

Ready for a clinician-led plan?

Clinical review determines the appropriate next step. No treatment is guaranteed.

THE CARE PATH

  1. We order your labs

  2. A licensed clinician reviews results and recommends a plan

  3. Rx sent directly to you when appropriate

Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.

Start your lab reviewExplore free educational tools